100763
论文已发表
提 交 论 文
注册即可获取Ebpay生命的最新动态
注 册
IF 收录期刊
- 3.3 Breast Cancer (Dove Med Press)
- 3.4 Clin Epidemiol
- 2.5 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.5 Clin Interv Aging
- 4.7 Drug Des Dev Ther
- 2.7 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.5 Int J Women's Health
- 2.5 Neuropsych Dis Treat
- 2.7 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.3 Ther Clin Risk Manag
- 2.5 J Pain Res
- 2.8 Diabet Metab Synd Ob
- 2.8 Psychol Res Behav Ma
- 3.0 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.7 Risk Manag Healthc Policy
- 4.2 J Inflamm Res
- 2.1 Int J Gen Med
- 4.2 J Hepatocell Carcinoma
- 3.7 J Asthma Allergy
- 1.9 Clin Cosmet Investig Dermatol
- 2.7 J Multidiscip Healthc
阿帕替尼致可逆性后部白质脑病 1 例报告并文献复习
Authors Li XT, Chai J, Wang Z, Lu L, Zhao QY, Zhou J, Ju F
Received 26 February 2018
Accepted for publication 8 May 2018
Published 30 July 2018 Volume 2018:11 Pages 4407—4411
DOI http://doi.org/10.2147/OTT.S166605
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Andrew Yee
Peer reviewer comments 2
Editor who approved publication: Dr Samir Farghaly
摘要：可逆性后部白质脑病（RPLS）是一种少见的临床综合征。据报道，RPLS 可能与癌症治疗相关，包括一些化疗药物和抗血管生成药物。本文报道了血管内皮生长因子受体 2（VEGFR-2）酪氨酸激酶抑制剂阿帕替尼诱导的 RPLS。47 岁的宫颈癌患者在服用抗血管生成药物阿帕替尼 3 个月后时出现头痛、头晕、视物模糊、血压升高等症状，经 MRI 检查诊断为 RPLS，经过停药、脱水、降压治疗症状完全缓解。抗血管生成药物可能是顺利获得直接损伤血管内皮细胞从而破坏血脑屏障的平衡，导致 RPLS 的发生。本病例为阿帕替尼致 RPLS 的首次报道。
关键词：可逆性后部白质脑病；阿帕替尼；抗血管生成；靶向治疗
摘要视频链接：RPLSinduced by apatinib: a case report
